Preclinical research identifies CREB1 as new therapeutic target downstream of frequently mutated genes Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, interact through the CREB1 protein […]